Overall, IL-1 inhibitors, TNF-α inhibitors, and JAK inhibitors demonstrated therapeutic benefits in reducing RA activity, showing associations with higher ACR20, ACR50, and ACR70 response rates. This evidence concerns the gene IL1A and rheumatoid arthritis.